Early Luteal Phase Progesterone Kinetics After hCG-Induced Ovulation in Modified Natural Cycle

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-15

Study Completion Date

2030-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This pilot study evaluates how progesterone levels change after hCG-triggered ovulation in modified natural cycles. Forty women preparing for frozen embryo transfer will have blood tests over 6 days to monitor hormone levels. The goal is to understand whether hCG affects the timing of the luteal phase and embryo implantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Progesterone Levels During Ovulation and Luteal Phase

NCT05076981

Infertility, Female

COMPLETED

The Effect of Luteal Blood Progesterone Levels on Ongoing Pregnancy Rates

NCT04128436

Luteal Phase Progesterone Levels

COMPLETED NA

Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles

NCT04758871

Frozen Embryo Transfer Hormone Replacement Therapy Dydrogesterone +1 more

COMPLETED PHASE4

Progesterone Rise in Agonist Versus Antagonist in Vitro Fertilization (IVF) Cycles

NCT01191710

Pregnancy Outcome After In Vitro Fertilization (IVF)

UNKNOWN PHASE4

Pregnancy Outcomes of Patients Having NC-FET Regarding the Progesterone Levels

NCT05690360

Infertility

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Luteal Phase Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

hCG

Intervention Type DRUG

Subcutaneous injection of 250 µg of recombinant hCG (Ovitrelle®)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hCG

Subcutaneous injection of 250 µg of recombinant hCG (Ovitrelle®)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 1 follicle of 17 mm or more
* Endometrium of 6 mm or more
* Plasma luteinizing hormone (LH) less than 2 times basal level (measured at the beginning of the cycle between D1 and D4) and progesteronemia less than 1.5 ng/mL
* For whom ovulation induction with recombinant hCG (Ovitrelle) is then proposed (standard care).

care)

Exclusion Criteria

* Patient whose venous capital contraindicates repeated blood sampling over a short period of time over a short period.
* Patient treated with exogenous natural progesterone (vaginal or injectable) which may interfere or synthetic progesterone, which may interfere with endogenous progesterone secretion.
* Patient who has not given written consent to participate in the study.
* Patient not fluent in French.
* Patient under guardianship, curators or without social security coverage.
* Patient participating in another study with an ongoing exclusion period or other interventional research with no ongoing exclusion period involves the use of a drug or procedure capable of altering progesterone levels .

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes